cystic fibrosis

People interested in knowing more about gene editing and its therapeutic applications can now download a document prepared by the American Society of Gene & Cell Therapy (ASGCT). The document, titled “Therapeutic Gene Editing: An ASGCT White Paper,” is intended as background information for policymakers, patients, and the general public…

A study evaluating the impact of palliative care on patients with serious diseases, such as cystic fibrosis (CF), and their caregivers, found it to improve patients’ quality of life and disease symptoms, and brought a sense of satisfaction to both patients and their caregivers. Palliative care, however, did not improve survival.

Scientists at the University of Queensland, Australia, are focusing their efforts on what is one of world’s leading sources of antibiotic resistance — biofilm. Biofilms refer to the communities of bacteria and other microorganisms that adhere to surfaces in thin layers and secrete a protective coating that diminishes the effects of antibiotics. Biofilms are considered…

Pulmatrix announced that it will present promising new preclinical data on PUR1900, an investigative inhaled therapy for fungal lung infections in cystic fibrosis patients, in a poster presentation at the North American Cystic Fibrosis Conference (NACFC), taking place Oct. 27–29 in Florida. Patients with cystic fibrosis (CF) often suffer from a condition called allergic bronchopulmonary…

Aradigm Corporation and the Woolcock Institute are collaborating to develop cutting-edge nanotechnologies that target the bacterial and fungal biofilms often present in patients with cystic fibrosis (CF), non-CF bronchiectasis (non-CF BE), and other chronic lung diseases. The most prevalent pathogenic microorganisms found in CF and non-CF BE patients are Haemophilus influenzae, Pseudomonas aeruginosa,…

Researchers at the University of Geneva  discovered that a protein of Pseudomonas aeruginosa, called Host factor q (Hfq), reacts with metals and helps the bacteria gain resistance to multiple classes of antibiotics. P. aeruginosa is an opportunistic bacterial pathogen that causes serious and diverse infections  by producing a broad range of virulence…

A team of scientists from Ulster University, in Northern Ireland, United Kingdom, have joined a nearly $980,000  global research study seeking alternative treatment options for patients with cystic fibrosis-related diabetes (CFRD). The new three-year Strategic Research Centre (SRC) study is the first of its kind funded by the Cystic Fibrosis Trust…

A recent study from Belgium showed that a common bacterium found in the lungs of people with cystic fibrosis (CF) might be converted to a less dangerous form, and could possibly aid in the development of treatments for the disease. The research report, “Effect of Shear Stress on Pseudomonas aeruginosa Isolated…

PTC Therapeutics, Inc. recently announced the recipients of its global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, which supports nonprofit associations assisting the cystic fibrosis (CF) community. The STRIVE Program recognizes the vital role patient advocacy groups play in giving voice to individuals affected by these rare…

A Chicago Medical School review explored the scientific evidence behind three natural compounds — genistein, curcumin, and resveratrol — often proposed for the treatment of cystic fibrosis (CF). The review concluded that while the mechanisms by which these substances function should be further investigated as potential drug treatments, there is little evidence…